University of California, Los Angeles (UCLA) - Medical Center
Welcome,         Profile    Billing    Logout  
 7 Trials 
19 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Eradat, Herbert
ALLELE, NCT03394365 / 2017-002949-30: Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy

Checkmark Data from ALLELE trial for post-transplant lymphoproliferative disease
Dec 2021 - Dec 2021: Data from ALLELE trial for post-transplant lymphoproliferative disease
Recruiting
3
66
Europe, Canada, US, RoW
tabelecleucel, tab-cel®, ATA129, EBV-CTL
Atara Biotherapeutics
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications
08/25
06/27
CRESCENDO, NCT06072131: To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

Recruiting
3
504
Europe, US, RoW
Belinostat Injection, Beleodaq®, Pralatrexate Injection, Folotyn®, CHOP, Cyclophosphamide, Hydroxydaunorubicin (doxorubicin), Oncovin (vincristine), and Prednisone, COP, Cyclophosphamide, Oncovin (vincristine), and Prednisone
Acrotech Biopharma Inc.
Peripheral T Cell Lymphoma
07/30
11/30
TELLOMAK, NCT03902184 / 2018-003969-33: IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma

Checkmark Preliminary efficacy data from TELLOMAK trial for Sezary syndrome at ASH 2022
Dec 2022 - Dec 2022: Preliminary efficacy data from TELLOMAK trial for Sezary syndrome at ASH 2022
Checkmark Data from stage 2 cohort of TELLOMAK trial for mycosis fungoides
Sep 2022 - Sep 2022: Data from stage 2 cohort of TELLOMAK trial for mycosis fungoides
Checkmark Preliminary data from cohort 2 of TELLOMAK trial for mycosis fungoides
More
Active, not recruiting
2
170
Europe, US
IPH4102, lacutamab
Innate Pharma
Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome
10/23
01/26
EBVision, NCT04554914 / 2020-000177-25: A Study to Evaluate Tabelecleucel in Participants with Epstein-barr Virus-associated Diseases

Hourglass Jan 2023 - Dec 2023 : From P2 trial for Epstein-Barr virus-associated sarcoma
Recruiting
2
190
Europe, US
Tabelecleucel, tab-cel®, ATA129, EBV-CTLs
Atara Biotherapeutics
Epstein-Barr Virus (EBV)-associated Diseases, EBV+ Lymphoproliferative Disease with Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease with Acquired (non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD), EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications, EBV+ Sarcomas, Leiomyosarcoma
06/27
05/29
TRANSCEND-CLL-004, NCT03331198: Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Checkmark Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Jan 2023 - Jan 2023: Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Checkmark From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Dec 2019 - Dec 2019: From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Hourglass Oct 2018 - Dec 2018 : Completion of enrollment in P2 TRANSCEND WORLD trial for 3L DLBCL
More
Recruiting
1/2
320
Canada, US
JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax
Juno Therapeutics, a Subsidiary of Celgene
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
11/27
11/27
ONO-7018-01, NCT05515406: A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL

Recruiting
1
108
US
ONO-7018
Ono Pharmaceutical Co. Ltd
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
12/27
12/27
Aslam, Saima
CPAT-ISR, NCT05077254: COVID Protection After Transplant-Immunosuppression Reduction

Active, not recruiting
2
400
US
Pfizer-BioNTech COVID-19 Vaccine 2023-2024, mRNA COVID-19 vaccine, BNT162b2 mRNA COVID-19 vaccine, SARS-CoV-2 RNA vaccine, Comirnaty, Moderna COVID-19 Vaccine 2023-2024, Moderna COVID-19 vaccine, SARS-CoV-2 vaccine, Spikevax, SOC IS Regimen, Standard of Care transplant immunosuppression regimen, Immunosuppression (IS), mycophenolate mofetil (MMF) or equivalent, tacrolimus, SOC IS Reduction, Standard of Care (SOC) transplant immunosuppression regimen, Immunosuppression (IS) Reduction
National Institute of Allergy and Infectious Diseases (NIAID), PPD, Johns Hopkins University
Kidney Transplant Recipients, Liver Transplant Recipients
02/24
03/25
CPAT-SG, NCT05518487: COVID Protection After Transplant - Sanofi GSK () Study

Active, not recruiting
2
80
US
Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine
National Institute of Allergy and Infectious Diseases (NIAID), PPD, Johns Hopkins University, Sanofi Pasteur, a Sanofi Company
COVID-19, Kidney Transplant
02/24
07/25
COLT, NCT06075745: Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates

Recruiting
2
416
US
CMV-MVA Triplex, Placebo for CMV-MVA Triplex
National Institute of Allergy and Infectious Diseases (NIAID)
Liver Transplant
06/27
02/28
diSArm, NCT05184764: Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia

Recruiting
1/2
50
US, RoW
AP-SA02, Placebo
Armata Pharmaceuticals, Inc., United States Department of Defense
Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia, Bacteremia Staph, Bacteremia Due to Staphylococcus Aureus
12/24
03/25
NCT06263426: Kidney Transplantation From Donors With HIV: Impact on Rejection and Long-Term Outcomes (Expanding HOPE Kidney)

Recruiting
N/A
200
US
HIV D+/R+, HIV D-/R+
Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID)
Hiv
09/28
09/29
NCT03734393: HOPE in Action Trial of HIV+ Deceased Donor Liver Transplants for HIV+ Recipients

Active, not recruiting
N/A
80
US
HIVD+/R+
Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID)
Hiv
04/25
06/25
PREVENT-HCV, NCT05653232: Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients

Recruiting
N/A
120
US
Prophylaxis (P2W), Transmit and Treat (T&T)
Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID)
HCV
09/25
03/27
Cameron, Robert
NCT05228015: Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors

Terminated
1
67
Europe, US, RoW
IK-930, Osimertinib
Ikena Oncology
Solid Tumors, Adult, Solid Tumor, Malignant Pleural Mesothelioma (MPM), Epithelioid Hemangioendothelioma (EHE), NF2 Deficient Mesothelioma, Other NF2 Deficient Solid Tumors and Solid Tumors with YAP1/TAZ Fusion Genes, NF2 Deficiency, YAP1 or TAZ Gene Fusions
08/24
09/24
VALOR, NCT02984761: Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy

Recruiting
N/A
670
US
Stereotactic Radiotherapy, Stereotactic Body Radiation Therapy (SBRT) or Stereotactic Ablative Radiotherapy (SAbR), Anatomic Pulmonary Resection, Lobectomy or Anatomic Segmentectomy
VA Office of Research and Development
Lung Neoplasm
09/26
09/27
Calzada, Yesenia
diSArm, NCT05184764: Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia

Recruiting
1/2
50
US, RoW
AP-SA02, Placebo
Armata Pharmaceuticals, Inc., United States Department of Defense
Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia, Bacteremia Staph, Bacteremia Due to Staphylococcus Aureus
12/24
03/25
NCT05558904: An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer

Recruiting
1/2
60
US
Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside, a-methyl-4[18F]-4-deoxy-D-glucopyranoside, Alpha-methyl-4-[F-18]-fluoro-4-deoxy-d-glucopyranoside, Me-4(18F)DG, Me-4FDG, Me4FDG, METHYL 4-DEOXY-4-FLUORO-.ALPHA.-D-GLUCOPYRANOSIDE. F-18, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Laboratory Biomarker Analysis, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging
Jonsson Comprehensive Cancer Center, LUNGevity Foundation, American Cancer Society, Inc.
Lung Adenocarcinoma
10/25
10/26
REVITA-T2Di, NCT04419779: Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes

Suspended
N/A
320
Europe, US
Duodenal Mucosal Resurfacing (DMR), Duodenal Mucosal Resurfacing (Sham)
Fractyl Health Inc.
Type 2 Diabetes
06/25
01/26
Allyn, Paul
diSArm, NCT05184764: Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia

Recruiting
1/2
50
US, RoW
AP-SA02, Placebo
Armata Pharmaceuticals, Inc., United States Department of Defense
Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia, Bacteremia Staph, Bacteremia Due to Staphylococcus Aureus
12/24
03/25

Download Options